Abstract
Ovarian cancer, the worldwide leading cause of gynecological cancer-related death, is primarily treated by surgery followed by platinum chemotherapy. Though the tumor initially responds to the treatment, only 30% of 5 year survival period has been recorded and this is mainly attributed to the acquired chemo resistance and frequent recurrence of tumor. Combination chemotherapy as well, led to therapeutic failure due to non-specificity and subsequent side effects. However, polymer mediated drug delivery aids in overcoming these impediments. In particular, three dimensional macromolecule “Dendrimer” with its unique properties and numerous functionalities offer various advantages over the conventional approach and may improve the treatment outcome in patients with ovarian cancer. The present review highlights the various strategies employed using dendrimers to achieve targeted drug delivery and enhanced therapeutic efficacy in ovarian cancer.
Keywords: Ovarian cancer, asymptomatic, drug delivery systems, dendrimer, strategies, targeted drug delivery.
Current Pharmaceutical Design
Title:Effective Strategies and Applications of Dendrimers in the Treatment of Ovarian Cancer
Volume: 23 Issue: 21
Author(s): Akila Kesavan, Suresh Babu Pakala, Suresh K. Rayala*Ganesh Venkatraman*
Affiliation:
- Department of Biotechnology, IIT-M, Chennai-36,India
- Department of Human Genetics, Faculty of Biomedical Sciences, Technology & Research, & Sri Ramachandra Center for Biomedical Nanotechnology, Sri Ramachandra University, Porur, Chennai-600116, Tamil Nadu,India
Keywords: Ovarian cancer, asymptomatic, drug delivery systems, dendrimer, strategies, targeted drug delivery.
Abstract: Ovarian cancer, the worldwide leading cause of gynecological cancer-related death, is primarily treated by surgery followed by platinum chemotherapy. Though the tumor initially responds to the treatment, only 30% of 5 year survival period has been recorded and this is mainly attributed to the acquired chemo resistance and frequent recurrence of tumor. Combination chemotherapy as well, led to therapeutic failure due to non-specificity and subsequent side effects. However, polymer mediated drug delivery aids in overcoming these impediments. In particular, three dimensional macromolecule “Dendrimer” with its unique properties and numerous functionalities offer various advantages over the conventional approach and may improve the treatment outcome in patients with ovarian cancer. The present review highlights the various strategies employed using dendrimers to achieve targeted drug delivery and enhanced therapeutic efficacy in ovarian cancer.
Export Options
About this article
Cite this article as:
Kesavan Akila, Pakala Babu Suresh, Rayala K. Suresh*, Venkatraman Ganesh*, Effective Strategies and Applications of Dendrimers in the Treatment of Ovarian Cancer, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170223165541
DOI https://dx.doi.org/10.2174/1381612823666170223165541 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review: The Anti-inflammatory, Anticancer and Antibacterial Properties of Four Kinds of Licorice Flavonoids Isolated from Licorice
Current Medicinal Chemistry Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer
Current Pharmaceutical Design Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology Stem Cell Therapies
Recent Patents on Regenerative Medicine Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry